HISTOGEN INC - HSTO STOCK NEWS

Histogen Inc. (OTC: HSTO) has announced the adjournment of its special meeting of stockholders to January 4, 2024. The estimated cash distribution to shareholders is in the range of $0.30 to $0.41 per share of common stock, subject to available cash. The company urges stockholders to vote 'FOR' the Dissolution Proposal and the Adjournment Proposal.

Histogen Inc. (OTC: HSTO) has adjourned its special meeting of stockholders to December 14, 2023. The meeting will continue to be held via live webcast. The company will continue to solicit votes from its stockholders with respect to both proposals set forth in the Proxy Statement. The Histogen Board of Directors unanimously recommends that stockholders vote 'FOR' the Dissolution Proposal and 'FOR' the Adjournment Proposal.

Histogen Inc. announces Plan of Dissolution, discontinues clinical development programs, and reduces workforce.

Histogen Inc. (HSTO) announced a positive outcome from a preclinical study showing that emricasan significantly reduces lesion size and bacterial burden in a mouse model of MRSA skin infection. Conducted with various treatment groups, results indicated that emricasan alone outperformed doxycycline, a standard antibiotic. The company aims to initiate clinical trials for acute bacterial skin and skin structure infections by the second half of 2023, following FDA approval to proceed. Emricasan, a pan-caspase inhibitor, has also shown promise in treating mild COVID-19 symptoms, with previous studies indicating its safety and efficacy. Histogen's pipeline includes other caspase inhibitors designed for inflammatory diseases.

Histogen Inc. (HSTO) has entered an exclusive license agreement with Johns Hopkins University for the use of emricasan in treating infections caused by various pathogens, including MRSA and SARS-CoV-2. This agreement significantly enhances Histogen's intellectual property portfolio, granting it operational freedom and exclusivity for its caspase inhibitor pipeline. Emricasan’s potential to improve immune response offers a novel treatment avenue amidst growing concerns over antibiotic resistance. Clinical development for treating acute bacterial skin and skin structure infections (ABSSSI) is expected to commence in the second half of 2023.

Histogen Inc. (HSTO) announced the issuance of US Patent No. 11,579,703 for caspase inhibitors, extending intellectual property protection until 2040. This patent covers CTS-2090, an orally active anti-inflammatory compound that has shown significant efficacy in models of ulcerative colitis, protecting against GI tract damage and weight loss. The company is also pursuing the use of emricasan for treating acute bacterial skin infections, including those caused by MRSA. With a growing pipeline of caspase inhibitors, Histogen aims to address various infectious and inflammatory diseases.

Histogen Inc. (NASDAQ: HSTO) has reported its financial results for 2022, highlighting a significant revenue increase driven by a one-time $3.75 million payment. The company's focus remains on developing emricasan for acute bacterial skin and structure infections. Clinical development for emricasan is expected to begin in mid-2023. However, the company has faced setbacks, including the termination of the HST 003 clinical trial and the suspension of HST 004 activities. Full-year revenue reached $3.8 million, while cash reserves stand at $12.1 million, adequate until January 2024. R&D expenses decreased to $5.0 million, while general and administrative costs rose to $9.4 million.